Finding antivirals that reduce mortality from severe respiratory viral infections has proven challenging. Phase 3 trials of baloxavir and pimodivir for severe influenza were unsuccessful (NCT03684044 and NCT03376321). Lopinavir–ritonavir and hydroxychloroquine are not efficacious in treating COVID-19.1,2 Interim results from the WHO-led, open-label, randomised SOLIDARITY trial3 of patients with COVID-19 report that 301 (11·0%) of 2743 patients analysed who received remdesivir and 303 (11·2%) of 2708 patients analysed who received standard care died by day 28 (Kaplan-Meier rate ratio [RR] 0·95, 95% CI 0·81–1·11; p=0·50).
No comments:
Post a Comment